GTx Inc. (NASDAQ:GTXI) was the target of a large drop in short interest in September. As of September 30th, there was short interest totalling 798,951 shares, a drop of 35.7% from the September 15th total of 1,242,509 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily volume of 118,218 shares, the days-to-cover ratio is currently 6.8 days.
GTXI has been the topic of a number of research reports. Jefferies Group reissued a “hold” rating and issued a $1.00 target price on shares of GTx in a research note on Friday, September 9th. Zacks Investment Research raised shares of GTx from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.
GTx (NASDAQ:GTXI) opened at 0.92 on Friday. The firm has a 50-day moving average of $0.74 and a 200-day moving average of $0.66. GTx has a 1-year low of $0.29 and a 1-year high of $1.15. The stock has a market capitalization of $130.56 million, a price-to-earnings ratio of 5.54 and a beta of 2.36.
GTx (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. Equities research analysts anticipate that GTx will post ($0.12) EPS for the current year.
A hedge fund recently raised its stake in GTx stock. BVF Inc. IL boosted its position in GTx Inc. (NASDAQ:GTXI) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,512,000 shares of the biopharmaceutical company’s stock after buying an additional 348,864 shares during the period. GTx comprises 1.4% of BVF Inc. IL’s investment portfolio, making the stock its 21st largest position. BVF Inc. IL owned about 8.12% of GTx worth $5,756,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 10.77% of the company’s stock.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.